TY - JOUR
T1 - Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients
AU - Mantovani, Giovanna
AU - Bastepe, Murat
AU - Monk, David
AU - De Sanctis, Luisa
AU - Thiele, Susanne
AU - Ahmed, S. Faisal
AU - Bufo, Roberto
AU - Choplin, Timothée
AU - De Filippo, Gianpaolo
AU - Devernois, Guillemette
AU - Eggermann, Thomas
AU - Elli, Francesca M.
AU - Garcia Ramirez, Aurora
AU - Germain-Lee, Emily L.
AU - Groussin, Lionel
AU - Hamdy, Neveen A.T.
AU - Hanna, Patrick
AU - Hiort, Olaf
AU - Jüppner, Harald
AU - Kamenický, Peter
AU - Knight, Nina
AU - Le Norcy, Elvire
AU - Lecumberri, Beatriz
AU - Levine, Michael A.
AU - Mäkitie, Outi
AU - Martin, Regina
AU - Martos-Moreno, Gabriel Ángel
AU - Minagawa, Manasori
AU - Murray, Philip
AU - Pereda, Arrate
AU - Pignolo, Robert
AU - Rejnmark, Lars
AU - Rodado, Rebeca
AU - Rothenbuhler, Anya
AU - Saraff, Vrinda
AU - Shoemaker, Ashley H.
AU - Shore, Eileen M.
AU - Silve, Caroline
AU - Turan, Serap
AU - Woods, Philip
AU - Zillikens, M. Carola
AU - Perez De Nanclares, Guiomar
AU - Linglart, Agnès
N1 - Funding Information:
The European Network on Pseudohypoparathyroidism (Euro-PHPnet), which promoted the consensus, was funded by an ESPE grant to A.L. The consensus statement and the series of consensus meetings were supported by funds from the COST action BM1208 on imprinting disorders (www.imprinting-disorders.eu), the ESPE, and the ESE. Travel costs and housing of the representatives of the APPES and of the PES were supported by their societies. We received no funding from pharmaceutical companies.
Publisher Copyright:
© 2020 S. Karger AG. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by physical findings that may include brachydactyly, a short stature, a stocky build, early-onset obesity, ectopic ossifications, and neurodevelopmental deficits, as well as hormonal resistance most prominently to parathyroid hormone (PTH). In addition to these alterations, patients may develop other hormonal resistances, leading to overt or subclinical hypothyroidism, hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable evidence for hormonal abnormalities, type 2 diabetes, and skeletal issues with potentially severe limitation of mobility. PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, radiological, and biochemical presentation, establishment of the molecular diagnosis is of critical importance for patients. It facilitates management, including prevention of complications, screening and treatment of endocrine deficits, supportive measures, and appropriate genetic counselling. Based on the first international consensus statement for these disorders, this article provides an updated and ready-To-use tool to help physicians and patients outlining relevant interventions and their timing. A life-long coordinated and multidisciplinary approach is recommended, starting as far as possible in early infancy and continuing throughout adulthood with an appropriate and timely transition from pediatric to adult care.
AB - Patients affected by pseudohypoparathyroidism (PHP) or related disorders are characterized by physical findings that may include brachydactyly, a short stature, a stocky build, early-onset obesity, ectopic ossifications, and neurodevelopmental deficits, as well as hormonal resistance most prominently to parathyroid hormone (PTH). In addition to these alterations, patients may develop other hormonal resistances, leading to overt or subclinical hypothyroidism, hypogonadism and growth hormone (GH) deficiency, impaired growth without measurable evidence for hormonal abnormalities, type 2 diabetes, and skeletal issues with potentially severe limitation of mobility. PHP and related disorders are primarily clinical diagnoses. Given the variability of the clinical, radiological, and biochemical presentation, establishment of the molecular diagnosis is of critical importance for patients. It facilitates management, including prevention of complications, screening and treatment of endocrine deficits, supportive measures, and appropriate genetic counselling. Based on the first international consensus statement for these disorders, this article provides an updated and ready-To-use tool to help physicians and patients outlining relevant interventions and their timing. A life-long coordinated and multidisciplinary approach is recommended, starting as far as possible in early infancy and continuing throughout adulthood with an appropriate and timely transition from pediatric to adult care.
UR - http://www.scopus.com/inward/record.url?scp=85089824135&partnerID=8YFLogxK
U2 - 10.1159/000508985
DO - 10.1159/000508985
M3 - Journal articles
C2 - 32756064
AN - SCOPUS:85089824135
SN - 1663-2818
VL - 93
SP - 182
EP - 196
JO - Hormone Research in Paediatrics
JF - Hormone Research in Paediatrics
IS - 3
ER -